PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth above 1.5x TRAW's 9.50%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.23%
Operating income growth above 1.5x TRAW's 9.50%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
18.34%
Net income growth above 1.5x TRAW's 10.83%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.95%
EPS growth 1.25-1.5x TRAW's 27.22%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
32.95%
Diluted EPS growth 1.25-1.5x TRAW's 27.22%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
21.91%
Share count expansion well above TRAW's 22.52%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
21.91%
Diluted share count expanding well above TRAW's 22.52%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth 1.25-1.5x TRAW's 36.83%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
46.06%
FCF growth 1.25-1.5x TRAW's 36.83%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Negative 10Y OCF/share CAGR while TRAW stands at 97.84%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
85.25%
5Y OCF/share CAGR at 75-90% of TRAW's 97.84%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
76.39%
3Y OCF/share CAGR at 75-90% of TRAW's 94.11%. Bill Ackman would press for improvements in margin or overhead to catch up.
-13944.86%
Negative 10Y net income/share CAGR while TRAW is at 92.26%. Joel Greenblatt sees a major red flag in long-term profit erosion.
85.03%
5Y net income/share CAGR similar to TRAW's 92.26%. Walter Schloss might see both on parallel mid-term trajectories.
64.22%
3Y net income/share CAGR 50-75% of TRAW's 91.66%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
5293.49%
10Y equity/share CAGR above 1.5x TRAW's 99.06%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
188.65%
5Y equity/share CAGR above 1.5x TRAW's 99.06%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
367.41%
Positive short-term equity growth while TRAW is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-38.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-22.47%
We cut SG&A while TRAW invests at 3.13%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.